To review gene regulation of HDL-cholesterol and discuss molecular abnormalities in HDL candidate genes that may lead to human pathologic states.
Introduction
Beginning with the clinical description of orange tonsils and associated absence of HDL-cholesterol in a brother and sister residing on Tangier Island more than 40 years ago, there has been considerable interest in understanding the genetics of HDL regulation in humans. During the past two decades, numerous candidates such as apolipoproteins, lipases, antioxidants, transfer proteins and regulators of cholesterol efflux and esterification have been studied and at least 25 candidates are believed to contribute to the anti-atherothrombotic effects of HDL. Genome wide scans have supplemented these efforts with identification of 22 different loci in 14 chromosomal regions contributing to HDL levels in humans (see ref.
]). Because genetic influences are the primary contributors to HDL levels, the identification and characterization of variants have provided useful information related to genotype-phenotype relationships and attendant risk of vascular disease. However, the relationship between HDL concentration and cardiovascular disease is not as straightforward as initially hypothesized with several genetic hurdles offsetting this relationship at both ends of the HDL spectrum (e.g. apolipoprotein A1 Milano (Apo A1 Milano ) and cholesterol ester transfer protein (CETP) deficiency). Moreover, while the overwhelming majority of low HDL syndromes (20-40 mg/dL) result from polygenic influences, single gene defects are more likely to predominate with HDL 510 mg/dL in the absence of identifiable metabolic irregularities. This review evaluates genetic factors affecting HDL regulation in humans, with a focus on single gene variants that predispose to premature vascular disease and potential targets for therapeutic intervention aimed at maximizing HDLs' cardioprotective properties.
HDL genetic variants associated with low HDL cholesterol and human pathology
While at least 10 candidate genes are involved in the regulation of HDL metabolism, human pathology has only been consistently reported among several candidates in whom structural variation may cause low HDL.
ABCA1
ABC transporters are involved in the mobilization of various substrates across plasma membranes. Defective gene products have been implicated in pathologic conditions ranging from cystic fibrosis and acute bronchopulmonary aspergillosis to pseudoxanthoma elasticum (ABCC6), retinitis pigmentosa (ABCA4) and sitosterolemia (ABCG5/ABCG8). Mapped to 9q31.1 and expressed in liver, macrophages and steroidogenic tissues, ABCA1 mediates cholesterol efflux from macrophages to HDL. Defects in both ABCA1 alleles as a result of consanguinity or compound heterozygosity may result in Tangier disease, characterized by yellowishorange discoloration on tonsillar and mucosal surfaces owing to accumulation of carotenoid pigment and retinyl esters in reticuloendothelial cells. Lipid accumulation in Schwann cells may result in peripheral neuropathy [2] .
As with other ABC proteins, ABCA1 consists of two transmembrane domains each composed of six hydrophobic membrane spanners. Surrounding each transmembrane domain is the ATP binding cassette which contains the Walker A and B motifs connected by a family specific signature region. Extracellular loops containing glycosylation sites are present within the hydrophobic membrane spanners. At least 30 different structural variants have now been reported in ABCA1 and encompass most of the regulatory regions (Table 1 ). Tangier fibroblasts demonstrate reduced cholesterol efflux with the greatest inhibition of efflux correlating with HDL levels [3] . Compared with missense mutations, other ABCA1 variants (e.g. frameshift and in-frame deletions) that encode a truncated protein appear to be less amenable to transcriptional upregulation by oxysterols [4 . ], which are presently under active investigation as potential targets for enhancing reverse cholesterol transport (see below).
In addition to Tangier disease, a single defective ABCA1 allele has been reported to cause familial hypoalphalipoproteinemia (FHA), a disorder characterized by moderately low HDL-cholesterol and premature coronary heart disease (CHD). To date, affected FHA subjects with ABCA1 variants have considerably lower HDL levels than more typically identified in CHD patients (e.g. 520 mg/dl compared to 430 mg/dl). This suggests that FHA caused by ABCA1 variants likely accounts for only a minority of such cases in the population. In fact, one recent population study of FHA subjects (n = 515) found no significant association between ABCA1 polymorphisms and low HDL-cholesterol [5 . ]. Similarly, fibroblasts from FHA subjects are heterogenous in cholesterol efflux capacity; a range of normal efflux to 50% reduction [6] has been correlated to HDL levels. In association with reduced cholesterol efflux is enhanced carotid intima medial thickness, a non-invasive predictor for future CHD event rates [ Peroxisome proliferator-activated receptors (PPARs) also enhance ABCA1 gene expression by inducing LXR. Fibrates (PPARa) and glitazones (PPARg) represent two classes of PPAR activators that may raise HDL cholesterol through this pathway [14] .
Apolipoprotein A1
As the primary apolipoprotein of HDL, Apo A1 serves as a cofactor for cholesterol esterification and is an important component of reverse cholesterol transport. Apolipoprotein A1 consists of four coding regions and is complexed with apos C3 and A4 on chromosome 11. Complete apo A1 deficiency owing to chromosomal aberrations or deletions results in premature CHD [15] . The impact of genetic variants in apo A1 is highly variable; affected subjects may attain an elderly age without CHD [16 . ] whereas others may be at increased risk in association with other CHD risk factors [17] . Two notable variants, apo A1 Milano and apo A1 Paris are associated with reduced vascular risk. Recent data evaluating apo A1 Milano have indicated that the additional cysteine residue encoding by the amino acid substitution dimerizes with apo A2 [18] , facilitating reverse cholesterol transport despite very low HDLcholesterol levels. Affected subjects with apo A1 Milano also demonstrate reduced carotid intima-media thickness [19] and greater antioxidant capacity [20 . . ]. Transcriptional regulators of APOA1 include PPARa agonists, steroid hormones and and retinoids [21, 22] . A common variant in the apo A1 promoter (-76 G/A) has been shown to be associated with elevated HDL-cholesterol and apo A1 levels in some [23] but not other studies [24] . Fat feeding studies have suggested that the presence of this polymorphism was associated with greater LDL increases [25] and in a follow-up postprandial study, carriers of this polymorphism exhibited reduction in apo A4 in large triacylglycerol-rich lipoproteins following the fat load [26] . Although the mechanism between the postprandial changes observed in association with -76 G/A remains to be delineated, the increased postprandial response may reflect less efficient catabolism of triacylglycerol-rich lipoproteins with reduction in apo A4. HDL genetic variants associated with high HDL-cholesterol and variable human pathology Alterations in several HDL regulating genes that result in hyperalphalipoproteinemia (hypera) have not consistently been associated with cardioprotection. Scavenger receptor BI (SR-BI) deficiency has been included in this discussion even though molecular defects in humans that may impact on atherothrombosis await publication.
Cholesterol ester transfer protein deficiency
CETP is a key plasma protein that influences circulating levels of HDL-cholesterol by facilitating the transfer of esterified cholesterol from HDL to very low density lipoproteins (VLDL), and the transfer of triacylglycerol from VLDL particles to HDL [30] . In conditions where hypertriglyceridemia exists, the efficiency of transfer of triacylglycerol is enhanced leading to triacylglycerol enrichment and cholesterol depletion of HDL. This cholesterol-poor HDL particle is cleared more rapidly from the kidney, and thereby leads to lower circulating HDL-cholesterol levels.
The lipid profile typically seen in subjects with CETP deficiency includes elevated HDL-cholesterol levels with LDL-cholesterol levels generally in the normal range [31] . The HDL 2 subfraction is increased and enriched with cholesterol, consistent with the fact that CETP is unable to facilitate the transfer of esterified cholesterol from HDL 2 to VLDL. Some investigators have suggested that despite the elevations in plasma HDL-cholesterol levels, these particles are dysfunctional and may not be cardioprotective [32] , while others suggest that CETP deficiency is associated with a low prevalence of coronary artery disease [33] .
The CETP gene is located on chromosome 16 and consists of 16 exons and 15 introns and is a member of the lipopolysaccharide binding protein gene family [34] . Most cases of CETP deficiency have been described in Japanese kindreds but cases have also been described in Caucasian and other Asian populations. The first Japanese subject identified as CETP deficient was found to have a G-to-A mutation in the 5'-splice donor site of intron 14 [35] . Other genetic permutations include a missense mutation in exon 15 (442D:G) and several polymorphisms in introns 1 and 8.
The association of CETP deficiency and atherosclerosis had been examined in males of Japanese ancestry in the Honolulu Heart Study [36] . The two CETP gene mutations, exon 15 442D:G and intron 14 G:A, were associated with increased HDL-cholesterol and decreased CETP levels. Increased risk for CHD was found in men with the mutations, particularly 442D:G, and HDL-cholesterol levels between 41 and 60 mg/dl, while men with or without mutations and HDL-cholesterol levels 460 mg/dl had a lower prevalence of CHD. However, these data have been challenged and a recent prospective analysis found no significant association between CETP mutations (in heterozygotes) and CHD [37 . ]. In a clinical trial using the CETP inhibitor, JTT-705, it was shown that the compound effectively raised HDL-cholesterol by 34% and decreased LDL by 7%, without major side effects [38 . ]. Taken together, these studies suggest that partial inhibition or deficiency of CETP may not be a deleterious effect. Importantly, clinical outcome studies are needed to be sure that raising HDL-cholesterol via CETP inhibition is of clinical benefit.
Hepatic lipase deficiency
Hepatic lipase is a glycoprotein of approximately 65 kDa and is synthesized in hepatocytes, then secreted and bound to hepatocyte and hepatic endothelial surfaces. Hepatic lipase specifically catalyzes the hydrolysis of triglycerides, diglycerides and phospholipids in native lipoproteins. In animal studies Lambert et al. [39] have shown that hepatic lipase is involved in the selective uptake of cholesterol ester from HDL.
The human hepatic lipase gene, LIPC, is located on chromosome 15q21. It comprises 9 exons and 8 introns, and spans a length of more than 30 kb. It encodes a protein of 449 amino acids with a signal peptide of 23 amino acids [40, 41] . Four polymorphisms have been detected in relation to the human hepatic lipase gene. They are: -250 G to A, -514 C to T, -710 T to C, and -763 A to G. Deeb and Peng [42] examined the promoter polymorphisms at positions -250 and -514 to determine whether they have any effect on hepatic lipase activity and whether they are in linkage disequilibrium. They reported that the -514 C?T allele is responsible for decreased hepatic lipase activity.
Vega and colleagues [43] reported the frequency of the -514 T allele to be significantly higher in AfricanAmericans (0.52) than in white Americans (0.17, P50.0001). Nie et al. [44] researched two polymorphisms in the coding region of the hepatic lipase gene: an A?G substitution at +651 (ASP?SER at codon 193), and an A?C substitution at +1075 that (LEU?SER) (LEU?PHE) at codon 334. The +651 G allele was twice as common in African-American men than in white men. The +1075 C allele was nearly 20 times more common in African-American men compared to white men. This study adds further insight to the genetic predisposition of African-Americans to higher HDLcholesterol and lower hepatic lipase activity. The +651, +1075 and -514 alleles are associated with decreased hepatic lipase activity in African-Americans. Recent data evaluating polymorphisms in endothelial lipase [45 . . ] have also disclosed ethnic differences that may be associated with high HDL. However, the clinical relevance of these molecular alterations remains to be determined [46] .
Scavenger receptor class B type I deficiency
The HDL receptor, scavenger receptor class B, type I (SR-BI), was isolated and characterized as a functional receptor by Acton et al. [47] . It is a member of the scavenger receptor class B family, whose members also include CD36 and LIMPII [48] . SR-BI participates in the selective uptake of cholesterol ester and is regulated by a number of factors including corticotrophin, estrogens, testosterone, cyclic AMP, gonadotropins, PPARa and PPARg agonists, and polyunsaturated fatty acids [49, 50, 51 . ,52-54]). A number of ligands bind with high affinity to SR-BI, including LDL, HDL, VLDL, modified LDL, and apolipoproteins [55] . In animal models, it has been shown to control levels of plasma HDL-cholesterol and non-HDLcholesterol levels, and the propensity for atherosclerosis [56] . The SR-BI gene has been localized to chromosome 12, it spans 75 kilobase pairs, and contains 13 exons [55] . The gene encodes a receptor protein of approximately 80 kDa, whose weight can vary based on its extent of glycosylation [55] . SR-BI is highly expressed in liver and steroidogenic tissue (adrenal, ovaries, and testes) [55] , and has been localized in atherosclerotic plaques (predominantly in macrophages) [56, 57] .
Acton et al. have identified and associated polymorphisms of the SR-BI gene locus in a white European population with plasma lipid levels and body mass index [58] . These investigators identified five variants at the human SR-BI gene locus, with three variants at exons 1 and 8 and intron 5 having allele frequences 41.0. The exon 1 variant was significantly associated with higher HDL and lower LDL levels in men but not in women. The exon 8 variant was associated with lower LDL levels in women but not in men, and the intron 5 variant showed an association with body mass index in women. The authors concluded that SR-BI might influence LDL and HDL levels.
Conclusion
Abnormalities in several HDL regulatory genes have been associated with human pathology. Specifically, HDL deficiency states may culminate in premature vascular disease (ABCA1 and apo A1) or renal insufficiency (LCAT) whereas variants causing CETP and hepatic lipase deficiency result in elevated HDL but they may also pose elevated risk of vascular disease. Potential pathologic (and/or cardioprotective) consequences of structural alterations in other HDL regulating genes (e.g. apos A2, A4, C1 and C3, phospholipid transfer protein, lipoprotein and endothelial lipase, SR-BI and paraoxynase) remain to be defined. Finally, considerable promise holds for agents that upregulate (e.g. LXR agonists) or downregulate (e.g. CETP inhibitors) gene expression of HDL target genes and enhance reverse cholesterol transport. 
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